Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and NEW YORK, 19 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), which is commercialising the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment for chronic kidney disease, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
| | For | % voted in favour | Against | % voted against | Withheld |
| Ordinary resolutions |
| | | | |
| 1 Receive and adopt the UK 2024 Annual Report | 215,649,238 | 99.86% | 298,365 | 0.14% | 40,760 |
| 2 Approve Directors' Remuneration Report | 187,117,898 | 86.76% | 28,544,007 | 13.24% | 326,458 |
| 3 Ratify the selection of CohnReznick | 215,624,372 | 99.92% | 178,413 | 0.08% | 185,578 |
| 4 Reappoint PKF Littlejohn LLP as Auditors | 215,760,810 | 99.91% | 184,281 | 0.09% | 43,272 |
| 5 Authorise Board to determine auditors' remuneration | 215,474,022 | 99.86% | 302,821 | 0.14% | 211,520 |
| 6 Authorise the issue of shares under the 2020 Equity Incentive Plan with Non-Employee Sub-Plan | 151,371,930 | 83.99% | 28,863,246 | 16.01% | 35,753,187 |
| 7 Authorise the Issue of Equity | 151,554,272 | 83.99% | 28,898,602 | 16.01% | 35,535,489 |
| | | | | | |
| Special resolutions |
| | | | |
| 8 Authorise Issue of Equity without Pre-emptive Rights | 151,648,214 | 84.04% | 28,799,536 | 15.96% | 35,540,613 |
| 9 Authorise Market Purchase of Ordinary Shares | 180,179,511 | 99.83% | 305,940 | 0.17% | 35,502,912 |
For further information, please contact:
| Renalytix plc | |
| James McCullough, CEO | Via Walbrook PR |
| | |
| Stifel (Nominated Adviser and Joint Broker) | Tel: 020 7710 7600 |
| Nicholas Moore / Nick Harland / Ben Good | |
| | |
| Oberon Capital (Joint Broker) | Tel: 020 3179 5300 |
| Mike Seabrook / Nick Lovering | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 |
| | |
| CapComm Partners | |
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix (www.renalytix.com)
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 10,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
